

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035013 A2

(51) International Patent Classification⁷: A61K 7/00

(21) International Application Number:
PCT/EP2003/013050

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0213101 21 October 2002 (21.10.2002) FR
60/432,619 12 December 2002 (12.12.2002) US

(71) Applicant (for all designated States except US):
L'OREAL [FR/FR], 14, rue Royale, F-75008 Paris
(FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SIMONNET, Jean-
Thierry [FR/FR], 53 bis, Avenue Carnot, F-94240 Cachan
(FR).

(74) Agent: DODIN, Catherine, L'Oreal - D.I.P.I., 25-29 Quai
Aulagmer, F-92600 Asnières (FR)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR DISSOLVING LIPOPHILIC COMPOUNDS IN AQUEOUS SOLUTION WITH AMPHIPHILIC
BLOCK COPOLYMERS, AND COSMETIC COMPOSITION

(57) Abstract: The invention relates to a process for dissolving at least one lipophilic compound in at least one aqueous phase,
characterized in that it comprises the step of associating the said lipophilic compound with an effective amount of at least one amphiphilic
block copolymer comprising at least one ionic and/or at least one nonionic hydrophilic polymer block, and at least one hydrophobic
polymer block.

WO 2004/035013 A2

Process for dissolving lipophilic compounds in aqueous solution with amphiphilic block copolymers, and cosmetic composition

The present invention relates to a process for dissolving lipophilic compounds with amphiphilic block copolymers. The invention also relates to novel cosmetic compositions resulting from the implementation of this process.

A large number of lipophilic molecules have very low solubilities in cosmetic solvents and have a tendency to recrystallize rapidly. Moreover, it is sought to avoid the presence of oily solvents for sensory reasons, or for reasons of compatibility in the case of dissolving two molecules with respective solvents that are incompatible with each other, or else for reasons of harmlessness if it is not desired to use solvents that can modify the barrier function of the skin.

Thus, in the case of sunscreens, in order to have substantial photoprotection, large proportions of solvent oils are necessary. This may be harmful to the final cosmetic feel of the composition containing them: oily, greasy feel. Formulation solutions that can increase the solubility of these sunscreens in water while at the same time avoiding the use of solvents such as ethanol and isopropanol, which are harmful to the integrity of the barrier function of the skin, have thus been sought.

It is known practice to combine certain compounds with lipophilic molecules, especially DHEA, in order to improve their solubility. However, none of these compounds is a block copolymer.

It is known practice to encapsulate lipophilic compounds in micelles of block copolymers, for example poly(ethylene oxide-propylene oxide) diblock or triblock copolymers. However, these block copolymers do not satisfactorily dissolve the lipophilic compound.

It is thus seen that it is necessary to develop families of readily available copolymers, enabling a satisfactory dissolution of the lipophilic compound by encapsulation in micelles that are stable at room temperature.

The Applicant has just discovered, surprisingly, that by combining a lipophilic compound with an effective amount of at least one block amphiphilic copolymer comprising at least one ionic or nonionic hydrophilic polymer block and at least one particular hydrophobic polymer block, the lipophilic compound can be satisfactorily dissolved, thus solving the drawbacks of the prior art.


One subject of the present invention is thus a process for dissolving lipophilic compounds in an aqueous phase using block copolymers.

A subject of the invention is also a cosmetic composition comprising a lipophilic compound and a block copolymer in aqueous phase.

- 5 Other characteristics, aspects and advantages of the invention will emerge on reading the detailed description that follows.

The process for dissolving at least one lipophilic compound in aqueous phase in accordance with the invention is characterized in that it comprises
10 the step of associating (physical combination) said lipophilic compound with an effective amount of at least one amphiphilic block copolymer comprising at least one ionic and/or at least one nonionic hydrophilic polymer block, and at least one hydrophobic polymer block obtained from at least one hydrophobic monomer chosen from :

- 15 - styrene and its derivatives such as 4-butylstyrene,
- vinyl acetate of formula $\text{CH}_2=\text{CH}-\text{OCOCH}_3$,
- vinyl ethers of formula $\text{CH}_2=\text{CHOR}$ in which R is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms,
20 - acrylonitrile,
- vinyl chloride and vinylidene chloride,
- caprolactone and caprolactam,
- alkenes such as ethylene, propylene, butylene and butadiene,
- alkylene oxides containing at least 4 carbon atoms and preferably from 4
25 to 6 carbon atoms,
- silicone derivatives producing, after polymerization, silicone polymers such as polydimethylsiloxane,
- hydrophobic vinyl monomers of formula (A) below:



in which:

- R is chosen from H, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$ and $-\text{C}_3\text{H}_7$,
- X is chosen from:
- alkyl oxides of $-\text{OR}'$ type in which R' is a linear, cyclic or branched,
35 saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a sulphonc group ($-\text{SO}_3^-$), a sulphate group ($-\text{SO}_4^-$), a phosphate group ($-\text{PO}_4\text{H}_2^-$); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$), a tertiary amine

group ($-NR_1R_2$) or a quaternary amine group ($-N^+R_1R_2R_3$) with R_1 , R_2 and R_3 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of $R' + R_1 + R_2 + R_3$ does not exceed 22; R' may also be a perfluoroalkyl radical, preferably containing from 1 to 18 carbon atoms;

- $-NH_2$, $-NHR'$ and $-NR'R''$ groups in which R' and R'' are, independently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 22 carbon atoms, with the proviso that the total number of carbon atoms of $R' + R''$ does not exceed 22, R' and R'' optionally being substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-OH$); a sulphonic group ($-SO_3^-$); a sulphate group ($-SO_4^-$); a phosphate group ($-PO_4H_2^-$); a primary amine group ($-NH_2$); a secondary amine group ($-NHR_1$); a tertiary amine group ($-NR_1R_2$) and/or a quaternary amine group ($-N^+R_1R_2R_3$) with R_1 , R_2 and R_3 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of $R' + R'' + R_1 + R_2 + R_3$ does not exceed 22; R' and R'' may also be perfluoroalkyl radicals, preferably containing from 1 to 18 carbon atoms.


The expression "effective amount of amphiphilic copolymer" means an amount that is sufficient for the copolymer to dissolve by itself the lipophilic compound in the aqueous phase, without recrystallization or creaming (for molecules that are oily at room temperature) of the said lipophilic compound.

The block copolymers used in the process according to the invention are especially those that can form micelles or lyotropic liquid crystal phases of lamellar, cubic (direct or inverse) or hexagonal (direct or inverse) type on contact with water. They are especially of diblock (A-B), triblock (B-A-B) or triblock (A-B-A) type, A corresponding to the ionic and/or nonionic hydrophilic polymer block and B to the hydrophobic polymer block.

The ionic hydrophilic polymer block may be obtained from water-soluble monomers or salts thereof, which may be chosen from:

- (meth)acrylic acid,
- acrylamido-2-methylpropanesulphonic (AMPS) acid,
- styrenesulphonic acid,
- vinylsulphonic acid and (meth)allylsulphonic acid,
- vinylphosphonic acid,

- maleic anhydride,
- itaconic acid,
- dimethyldiallylammonium chloride,
- quaternized dimethylaminoethyl methacrylate (DMAEMA),
- 5 - (meth)acrylamidopropyltrimethylammonium chloride (APTAC and MAPTAC),
- methylvinylimidazolium chloride,
- hydrophilic vinyl monomers of formula (A) below:



10


in which:

- R is chosen from H, -CH₃, -C₂H₅ and -C₃H₇,
- X is chosen from:
 - alkyl oxides of -OR' type in which R' is a linear, cyclic or branched,
 - 15 saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, substituted with at least one sulphonic group (-SO₃⁻) and/or sulphate group (-SO₄⁻) and/or phosphate group (-PO₄H₂⁻) and/or quaternary amine group (-N⁺R₁R₂R₃) with R₁, R₂ and R₃ being, independently of each other, a linear or branched, saturated or unsaturated hydro-
 - 20 carbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the atoms of R' + R₁ + R₂ + R₃ does not exceed 6; the radical R' being optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group (-OH); a primary amine group (-NH₂); a secondary amine group (-NHR₁) or a tertiary amine group
 - 25 (-NR₁R₂) with R₁, R₂ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R₁ + R₂ does not exceed 6;
 - -NH₂, -NHR' and -NR'R'' groups in which R' and R'' are, independ-
 - 30 ently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 6 carbon atoms, with the proviso that the total number of carbon atoms of R' + R'' does not exceed 6, R' and/or R'' being substituted with at least one sulphonic group (-SO₃⁻) and/or sulphate group (-SO₄⁻) and/or phosphate group (-PO₄H₂⁻) and/or
 - 35 quaternary amine group (-N⁺R₁R₂R₃) with R₁, R₂ and R₃ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the atoms of R' + R₁ + R₂ + R₃ does not exceed 6; the radicals R' and/or R'' being optionally substituted with a halogen atom

- (iodine, bromine, chlorine or fluorine); a hydroxyl group (-OH); a primary amine group (-NH₂); a secondary amine group (-NHR₁) or a tertiary amine group (-NR₁R₂) with R₁, R₂ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R'' + R₁ + R₂ does not exceed 6.

The ionic hydrophilic polymer block may also be polyethyleneimine.

- 10 The ionic hydrophilic polymer block may also be obtained from hydrophobic monomers, the said hydrophobic monomers being present in an amount that is small enough for the ionic hydrophilic polymer block to be soluble in water. The hydrophobic monomers may be chosen from:
- styrene and its derivatives such as 4-butylstyrene,
 - 15 - vinyl acetate of formula CH₂=CH-OCOCH₃,
 - vinyl ethers of formula CH₂=CHOR in which R is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms,
 - acrylonitrile,
 - 20 - vinyl chloride and vinylidene chloride,
 - caprolactone,
 - hydrophobic vinyl monomers of formula (A) below:



in which:

- 25 - R is chosen from H, -CH₃, -C₂H₅ or -C₃H₇,
- X is chosen from:
 - alkyl oxides of -OR' type in which R' is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms,
 - 30 - -NH₂, -NHR' and -NR'R'' groups in which R' and R'' are, independently of each other, linear or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 6 carbon atoms, with the proviso that the total number of carbon atoms of R' + R'' does not exceed 6.
- 35 The ionic hydrophilic polymer block is preferably chosen from (meth)acrylic acid.


Said ionic hydrophilic polymer block could be neutralized, partly or totally, by using an organic or non organic base, such as sodium, ammonium,

lithium, calcium, magnesium, salts substituted by 1-4 alkyl groups containing 1-15 carbon atoms. Other suitable bases are mono-, di- or triethanolamine, aminoethylpropanediol, N-methyl glucamine, or basic aminoacids such as arginine or lysine.

5

The nonionic hydrophilic polymer block may be of polyoxyalkylenated type, for instance polyoxyethylene. It may also be polyvinylpyrrolidone (PVP). The nonionic hydrophilic polymer block may also be obtained from water-

- monomers chosen from:
- 10 - (meth)acrylamide,
 - N-vinylacetamide and N-methyl-N-vinylacetamide,
 - N-vinylformamide and N-methyl-N-vinylformamide,
 - N-vinyl lactams comprising a cyclic alkyl group containing from 4 to 9 carbon atoms, such as N-vinylpyrrolidone, N-butyrolactam and N-vinyl-
 - 15 caprolactam,
 - vinyl alcohol of formula $\text{CH}_2=\text{CHOH}$,
 - glycidyl (meth)acrylate,
 - hydrophilic vinyl monomers of formula (A) below:



20 in which:

- R is chosen from H, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$ and $-\text{C}_3\text{H}_7$,
- X is chosen from:

- alkyl oxides of $-\text{OR}'$ type in which R' is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6
- 25 carbon atoms, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R₁ and R₂ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to
- 30 6 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R₁ + R₂ does not exceed 6;

- $-\text{NH}_2$, $-\text{NHR}'$ and $-\text{NR}'\text{R}''$ groups in which R' and R'' are, independently of each other, linear or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 6 carbon atoms, with the proviso
- 35 that the total number of carbon atoms of R' + R'' does not exceed 6, R' and R'' optionally being substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R₁ and R₂ being, independently of each other, a linear or branched,

saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of R^* + R^* + R_1 + R_2 does not exceed 6.

The nonionic hydrophilic polymer block is preferably chosen from polyethylene oxide or polyoxyethylene (PEO) and polyvinylpyrrolidone (PVP).

Preferably, the hydrophilic polymer block is nonionic.

Preferably, the hydrophilic polymer block is an homo-polymer.

The hydrophobic polymer block is obtained from at least one of the monomers cited above. It may also be obtained from hydrophilic monomers, being present in an amount that is small enough for the hydrophobic polymer block to be hydrophobic.

The hydrophilic monomers may be chosen from the above-mentioned water-soluble monomers suitable from obtaining nonionic hydrophilic polymer block or ionic hydrophilic polymer block.

Preferably, the hydrophobic polymer block is an homo-polymer.

The hydrophobic polymer block is preferably obtained from at least one hydrophobic monomers chosen from styrene, tert-butylstyrene, methyl methacrylate, ethyl (meth)acrylate, n-butyl (meth)acrylate, tert-butyl (meth)acrylate, cyclohexyl acrylate, isobornyl acrylate, 2-ethylhexyl acrylate, ethyl perfluorooctyl acrylate, trifluoromethyl (meth)acrylate, polybutylene oxide or polyoxybutylene (POB), butadiene, ethylene, propylene and butylene.

The block copolymer is preferably chosen from the following block copolymers:

- polystyrene/polyoxyethylene
- polymethyl methacrylate/polyoxyethylene
- polybutyl methacrylate/polyoxyethylene
- polyoxybutylene/polyoxyethylene
- polycaprolactone/polyoxyethylene
- polyethylene/polyoxyethylene
- polyoxyethylene/polyoxybutylene/polyoxyethylene.

The molecular weight of the block copolymer may be between 1 000 and 500 000, preferably from 2000 to 100 000.

The molecular weight of the hydrophilic block may be between 600 and 300 000, preferably from 1200 to 60 000.

The molecular weight of the hydrophobic block may be between 400 and 200 000, preferably from 800 to 40 000.

5 The weight ratio A/B between the hydrophilic block A and the hydrophobic block B ratio may be between 1/100 and 50/1.

In addition, the weight concentration ratio between the lipophilic compound and the amphiphilic block copolymer used according to the invention is generally between 0.005 and 0.5 and preferably between 0.005 and 0.2.

10

The lipophilic compounds are preferably those with a solubility in water of less than 0.2% by weight. The measurement is performed by UV spectrometry or HPLC on an aqueous solution, prepared beforehand, of from 20 to 80°C for 2 hours, followed by cooling to 25°C. The assay is performed 15 24 hours after this preparation on the supernatant obtained after centrifuging the suspension to remove all crystals, or on the pellet in the case of solubilization of oily molecules, the centrifugation resulting in creaming of the portion that is not encapsulated in the micelles.


20 In order for the gain in solubility to be satisfactory, the solubility in the aqueous phase of the lipophilic compound encapsulated in the block copolymer must be at least 15 times greater than the "natural" solubility of the lipophilic compound in water.

Examples of lipophilic compounds that may be mentioned include emollients, anti-inflammatory agents, antibacterial agents, antifungal agents, 25 antiviral agents, anti-seborrhoeic agents, antiacne agents, keratolytic agents, antihistamines, anesthetics, cicatrizing agents, pigmentation modifiers, tanning accelerators, artificial tanning agents, liporegulators, anti-ageing and anti-wrinkle agents, refreshing agents, vascular protectors, insect repellants, deodorants, antidandruff agents, agents for preventing 30 hair loss, essential oils, which may be chosen especially from eucalyptus oil, lavandin oil, lavender oil, vetiver oil, Litsea cubeba oil, lemon oil, sandalwood oil, rosemary oil, camomile oil, savory oil, nutmeg oil, cinnamon oil, hyssop oil, caraway oil, orange oil, geraniol oil and cade oil, fragrances, sunscreens, antioxidants, free-radical scavengers and moisturizers. 35

Examples of lipophilic compounds that may also be mentioned include vitamins such as vitamin A (retinol) or esters thereof, vitamin E or esters thereof such as tocopheryl acetate, vitamin D or derivatives thereof and vitamin F or derivatives thereof; carotenes such as β -carotene and derivatives thereof such as lycopene, and salicylic acid derivatives, especially 40

those described in documents FR-A-2 581 542, EP-A-378 936 and EP-A-570 230.

The salicylic acid derivatives may be chosen especially from the derivatives of formula



5

in which:

R''_1 represents a hydroxyl radical or an ester of formula $-O-CO-R''_4$ in which R''_4 is a saturated or unsaturated aliphatic radical containing from 1 to 26 carbon atoms and preferably from 1 to 18 carbon atoms, or an amine or thiol function optionally substituted with an alkyl radical containing from 1 to 18 carbon atoms and preferably from 1 to 12 carbon atoms,

R''_2 and R''_3 , independently of each other, are in one of the positions 3, 4, 5 or 6 on the benzene nucleus and represent, independently of each other, a hydrogen atom or a radical: $-(O)_n-(CO)_m-R''_5$ in which n and m , independently of each other, are each an integer equal to 0 or 1, on condition that R''_2 and R''_3 are not simultaneously hydrogen atoms; and R''_5 represents a hydrogen, a saturated, linear, branched or cyclized aliphatic radical containing from 1 to 18 carbon atoms, an unsaturated radical containing from 3 to 18 carbon atoms, bearing one to nine conjugated or non-conjugated double bonds, the radicals possibly being substituted with at least one substituent chosen from halogen atoms (fluorine, chlorine, bromine or iodine), trifluoromethyl radicals, hydroxyl radicals in free form or esterified with an acid containing from 1 to 6 carbon atoms, or carboxyl radicals in free form or esterified with a lower alcohol containing from 1 to 6 carbon atoms, or an aromatic radical containing from 6 to 10 carbon atoms.

Preferably, the salicylic acid derivative is such that R''_5 represents a saturated aliphatic radical containing from 3 to 15 carbon atoms.

Preferably, the salicylic acid derivative is such that R''_1 represents a hydroxyl radical.


Preferably, the salicylic acid derivative is such that R''_5 is in position 5 of the benzene nucleus and R''_2 represents a hydrogen atom.

According to one preferred embodiment of the invention, the salicylic acid derivative is chosen from the 5-n-octanoylsalicylic, 5-n-decanoylsalicylic, 5-n-dodecanoylsalicylic, 5-n-octylsalicylic, 5-n-heptyloxysalicylic, 4-n-heptyloxysalicylic, 5-tert-octylsalicylic, 3-tert-butyl-5-methylsalicylic, 3-tert-

butyl-6-methylsalicylic, 3,5-diisopropylsalicylic, 5-butoxysalicylic, 5-octyloxysalicylic, 5-propanoylsalicylic, 5-n-hexadecanoylsalicylic, 5-n-oleoylsalicylic and 5-benzoylsalicylic derivatives, monovalent and divalent salts thereof, and mixtures thereof.

- 5 When it is a sunscreen, the lipophilic compound may be chosen from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives; camphor derivatives; triazine derivatives, preferably 1,3,5-triazine derivatives such as those described in patent applications US 4 367 390, US 4 724 137, EP 863 145, EP 517 104, EP 570 838, 10 EP 796 851, EP 775 698, EP 878 469, EP 933 376, EP 507 691, EP 507 692, EP 790 243 and EP 944 624; benzophenone derivatives; β,β' -diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bis-benzazoyl derivatives as described in patents EP 669 323 and US 2 463 264; 15 p-aminobenzoic acid (PABA) derivatives; methylene-bis(hydroxyphenylbenzotriazole) derivatives as described in patent applications US 5 237 071, US 5 166 355, GB 2 303 546, DE 197 26 184 and EP 893 119; screening polymers and screening silicones such as those described especially in patent application WO 93/04665; dimers derived 20 from α -alkylstyrene, such as those described in patent application DE 198 55 649; 4,4-diarylbutadienes as described in patent applications EP 0 967 200 and DE 197 55 649, and mixtures thereof.

One preferential 1,3,5-triazine is 2,4,6-tris[p-(2'-ethylhexyl-1'-oxycarbonyl)anilino]-1,3,5-triazine, which is a UV-B-active screening agent 25 that is known per se, which is in a solid form and which is sold especially under the trade name "Uvinul T150" by the company BASF. This product corresponds to the following formula:



in which R' denotes a 2-ethylhexyl radical.


- 30 Other 1,3,5-triazine derivatives used according to the invention that are particularly preferred are 2-[(p-(tert-butylamido)anilino]-4,6-bis[(p-(2'-

ethylhexyl-1'-oxycarbonyl)anilino]-1,3,5-triazine, 2,4-bis[[4-2-ethylhexyloxy]-2-hydroxy]phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4,6-tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine, and mixtures thereof.

- Among the dibenzoylmethane derivatives, it is most particularly preferred to use 4-(tert-butyl)-4'-methoxydibenzoylmethane, or butylmethoxydibenzoylmethane, sold especially under the trade name "Parsol® 1789" by the company Hoffmann Laroche.

According to the present invention, the lipophilic compounds may also be chosen from:

- (1) dehydroepiandrosterone (DHEA) and its precursors and chemical and biological derivatives, with the exception of cholesterol and its esters and plant sterols such as phytosterols and sitosterols, and esters thereof; dehydroepiandrosterone is a natural steroid produced essentially by the adrenal glands, corresponding to the formula



- It is known for its anti-ageing properties associated with its capacity to promote epidermal keratinization (JP-07 196 467) and to combat osteoporosis (US 5 824 671), or in the treatment of dry skin, on account of its ability to increase the endogenous production and secretion of sebum and to reinforce the skin's barrier effect (US 4 496 556). It has also been proposed to use DHEA sulphate against alopecia (JP-60 142 908) and to treat various signs of ageing such as wrinkles, loss of radiance of the skin and slackening of the skin (EP-0 723 775).

- The DHEA that may be used according to the invention is available, for example, from the companies Sigma and Akzo Nobel.


- The expression "DHEA precursor" means the immediate biological precursors thereof and also the chemical precursors thereof. Examples of biological precursors are pregnenolone, 17 α -hydroxypregnenolone, 5-androstenediol, 17 α -hydroxypregnenolone sulphate and 5-androstenediol sulphate. Examples of chemical precursors are sapogenins such as diosgenin (spirost-5-ene-3- β -ol), hecogenin, smilagenin and sarsapogenin, and also natural extracts containing them, in particular fenugreek and extracts of Dioscorea plants such as wild yam root.

- The expression "DHEA derivatives" means both the metabolic derivatives thereof and the chemical derivatives thereof. Metabolic derivatives which may be mentioned in particular include 7 α -hydroxy-DHEA, 7-keto-DHEA,

5-androstene-3 β ,17 β -diol (or adiol), 5-androstene-3 β ,17 β -diol sulphate and 4-androstene-3,17-dione, although this list is not limiting. Chemical derivatives that may be mentioned in particular include salts, in particular water-soluble salts such as DHEA sulphate, esters such as the hydroxycarboxylic acid esters of DHEA described in US 5 736 537 or other esters such as DHEA salicylate, acetate, valerate and enanthate;

(2) pentacyclic triterpene acids such as ursolic acid and oleanolic acid. They are present in plants such as rosemary. They are frequently used in pharmaceutical compositions for their numerous therapeutic properties, and especially for their anti-inflammatory, hepato-protective, diuretic, analgesic and antimicrobial properties, their inhibitory properties on certain enzymatic activities, and their antitumour properties. In the cosmetic field, ursolic acid is described, for example, as a constituent of an antiperspirant composition (FR A 2 541 895) and as an inhibitor of the activity of tyrosinase, a key enzyme in melanin synthesis (JP-58/57307).

(3) hydroxystilbenes, which are compounds corresponding to the general formula:



in which n is an integer between 1 and 4 inclusive and m is an integer between 1 and 5 inclusive. This formula includes the *cis* and *trans* compounds. According to the present invention, the term "hydroxystilbene" also covers the hydroxyalkyl derivatives of the compounds of formula (II).

Hydroxystilbenes are compounds that are found in the natural state in plants of the spermatophyte class and in particular in vine. In the cosmetic field, hydroxystilbenes are used, inter alia, as depigmenting agents (JP-87-192 040) or anti-ageing agents (FR-2 777 186).

Among the hydroxystilbenes that may be mentioned are mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa- and nonahydroxystilbenes, or hydroxyalkyl derivatives thereof.

According to the invention, the hydroxystilbenes may be used alone or as mixtures of any nature and may be of natural or synthetic origin. The hydroxystilbenes that may be used according to the invention are chosen from:

- 4'-hydroxystilbene,
- 2',4'-dihydroxystilbene,
- 3',4'-dihydroxystilbene,

- 4,4'-dihydroxystilbene,
- 2',4',4'-trihydroxystilbene,
- 3',4',4'-trihydroxystilbene,
- 2,4,4'-trihydroxystilbene,
- 5 3,4,4'-trihydroxystilbene,
- 3,5,4'-trihydroxystilbene,
- 2',3,4-trihydroxystilbene,
- 2,3',4-trihydroxystilbene,
- 2',2,4'-trihydroxystilbene,
- 10 2,4,4',5'-tetrahydroxystilbene,
- 2',3,4',5-tetrahydroxystilbene,
- 2,2',4,4'-tetrahydroxystilbene,
- 3,3',4',5-tetrahydroxystilbene,
- 2,3',4,4'-tetrahydroxystilbene,
- 15 3,3',4,4'-tetrahydroxystilbene,
- 3,3',4',5,5'-pentahydroxystilbene,
- 2,2',4,4',6-pentahydroxystilbene,
- 2,3',4,4',6-pentahydroxystilbene,
- 2,2',4,4',6,6'-hexahydroxystilbene.

20 Among these compounds, resveratrol (3,5,4'-trihydroxystilbene) is particularly preferred since it is naturally present in the skin of grape seeds and in wine. In this regard, the review by Soleas and collaborators (Clinical Biochemistry, vol. 30, No. 2, pages 91 - 113, 1997), which perfectly summarizes the state of knowledge regarding this compound and hydroxystilbenes, may be consulted.

25 (4) Isoflavonoids, a sub-class of flavonoids, which are formed from a 3-phenylchroman skeleton that is oxidized to a greater or lesser extent and that may bear various substituents. The term "isoflavonoid" covers several classes of compounds, among which mention may be made of isoflavones, 30 isoflavanones, rotenoids, pterocarpanes, isoflavans, isoflavan-3-enes, 3-arylcoumarins, 3-aryl-4-hydroxycoumarins, coumestanes, coumaronochromones or 2-arylbenzofurans. A full review of isoflavonoids, their sources and methods of analysis has been published in "The Flavonoids", Harbone editor (1988), chapter 5 entitled "Isoflavonoids" by P.M. Dewick, 35 pages 125-157.

The isoflavonoids used according to the invention have a solubility in water at room temperature (25°C) of less than 0.01% and may be of natural origin, that is to say extracts of an element of natural origin, usually a plant, or may have been obtained by chemical synthesis. Isoflavonoids of natural 40 origin are preferred.


An example of an isoflavonoid of natural origin that may be mentioned is genistin.

- A preferred sub-class of isoflavonoids is that of isoflavones, covering both the aglycone forms (daidzein, genistein and glycitein) and the glycosyl forms (daidzin, genistin, glycitin).

Processes for preparing isoflavones are described in particular in patents and patent applications WO 95/10530, WO 95/10512, US 5 679 806, US 5 554 519, EP 812 837 and WO 97/26269.

- Isoflavones are known in particular as antioxidants, for their free-radical-scavenging and depigmenting properties, and also for their capacity to inhibit the activity of sebaceous glands (DE-44 32 947). They have also been described as agents capable of preventing signs of ageing of the skin (JP 1-96106).

(5) aminophenol derivatives of formula



- in which R is a radical corresponding to one of the formulae (i), (ii) and (iii) below

(i) $-\text{CO}-\text{NR}_1\text{R}_2$

(ii) $-\text{CO}-\text{O}-\text{R}_3$

- (iii) $-\text{SO}_2-\text{R}_3$

in which R_1 represents a hydrogen atom or an optionally hydroxylated, saturated or unsaturated, linear or branched C_{1-6} alkyl radical,

R_2 represents a hydrogen atom or a radical chosen from optionally hydroxylated, saturated or unsaturated, linear, cyclic or branched C_{12} to C_{30} alkyl radicals, and

R_3 represents a radical chosen from saturated or unsaturated, linear, branched or cyclic C_{12} to C_{30} alkyl radicals, including fused polycyclic radicals, which are optionally hydroxylated.

- Examples of lipophilic compounds that are preferred according to the present invention which may be mentioned include dehydroepiandrosterone (DHEA), DHEA sulphate, 7α -hydroxy-DHEA, 7-keto-DHEA, prednisolone, prednisone, progesterone, pregnenolone, testosterone, diosgenin, hecogenin, ursolic acid, oleanolic acid, resveratrol (= 3,5,4'-trihydroxystilbene) and N-cholesteryloxycarbonyl-4-aminophenol, and isoflavonoids whose solubility in water at room temperature (25°C) is less than 0.01%.

A subject of the invention is also a cosmetic composition comprising at least one aqueous phase, at least one lipophilic compound and an effective amount of at least one block amphiphilic copolymer as above defined.

- 5 The lipophilic compound may be present in the composition in weight contents of between 0.001% and 10% of the total weight of the composition.

10 The method for implementing the block copolymer(s) and the lipophilic compound(s) to be combined will be chosen by a person skilled in the art as a function of the chemical nature of the polymer. Examples that will be mentioned include nanoprecipitation via a water-miscible solvent, dialysis or direct hydration of the pre-combined block copolymer/lipophilic compound mixture. Nanoprecipitation consists in co-dissolving, in a water-miscible organic solvent with a boiling point below that of water, the block
15 copolymer(s) and the lipophilic compound to be encapsulated and in introducing this organic solution more or less quickly into an aqueous phase, with stirring (for example using a magnetic bar, paddles or a turbomixer). The micelles or particles form instantaneously. The solvent is then evaporated off.

20 The dialysis method consists in co-dissolving, in a water-miscible to sparingly water-miscible organic solvent with a boiling point higher than that of water, the block copolymer(s) and the lipophilic compound to be encapsulated. This solution is introduced into a dialysis bag and dialysed against
25 water. The dialysis water is regularly renewed, until the solvent has been completely dialysed. The same method may be envisaged with surfactants, for instance octyl glucoside, instead of solvent. It is a concentrated aqueous solution of surfactants that dissolves the copolymer(s) and the lipophilic compound to give a clear solution. This solution is then dialysed until the
30 surfactant is completely removed.

Another method, known as the Bangham method, which is commonly used for making liposomes, may be used. This consists in dissolving, in an organic solvent, the block copolymer(s) and the lipophilic compound to be encapsulated, and then evaporating off the solvent so as to obtain a
35 uniform mixture of the block copolymer(s) and of the lipophilic compound to be encapsulated. A rotary evaporator may be used in the laboratory, an atomizer may be used industrially, or any other method for evaporating a solvent may be used. This mixture may then be hydrated directly, with stirring, using an aqueous solution.

40 In general, any method known to those skilled in the art for synthesizing liposomes and nanoparticles may be used.

According to one embodiment of the invention, the block amphiphilic copolymer is the sole solvent for the lipophilic compound in the composition.

5 The compositions according to the invention may also contain pigments or nanopigments (mean size of the primary particles: generally between 5 nm and 100 nm and preferably between 10 and 50 nm) of coated or uncoated metal oxides, for instance nanopigments of titanium oxide (amorphous or
10 crystallized in rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide, which are photoprotective agents that are well known per se, acting by physically blocking (reflection and/or scattering) UV radiation. Standard coating agents are, moreover, alumina and/or aluminium stearate. Such coated or uncoated metal oxide nanopigments
15 are described in particular in patent applications EP-A-0 518 772 and EP-A-0 518 773.

The compositions in accordance with the present invention may also contain standard cosmetic adjuvants chosen especially from fatty substances, organic solvents, ionic or nonionic thickeners, softeners, free-
20 radical scavengers, opacifiers, stabilizers, emollients, silicones, α -hydroxy acids, antifoams, moisturizers, vitamins, preserving agents, surfactants, fillers, sequestering agents, polymers, propellants, acidifying or basifying agents, dyes or any other ingredient usually used in cosmetics and/or dermatology, in particular to manufacture antisun compositions in the form
25 of emulsions.

The fatty substances may consist of an oil or a wax or mixtures thereof. The term "oil" means a compound that is liquid at room temperature. The term "wax" means a compound that is solid or substantially solid at room temperature, and which has a melting point generally above 35°C.
30 Oils that may be mentioned include mineral oils (vaseline); plant oils (sweet almond oil, macadamia oil, blackcurrant seed oil or jojoba oil); synthetic oils, for instance perhydrosqualene, fatty alcohols, fatty acids or fatty esters (for instance the C₁₂-C₁₅ alcohol benzoates sold under the name "Finsolv TN" by the company Finetex, octyl palmitate, isopropyl lanolate, triglycerides including those of capric/caprylic acids), ethoxylated or propoxylated
35 fatty esters and ethers; silicone oils (cyclomethicone preferably containing 4 or 5 silicon atoms, and polydimethylsiloxane or PDMS) or fluoro oils, and polyalkylenes.

Waxy compounds that may be mentioned include paraffin, carnauba wax,
40 beeswax and hydrogenated castor oil.

Among the organic solvents that may be mentioned are lower alcohols and polyols.

The thickeners may be chosen especially from crosslinked polyacrylic acids, modified or unmodified guar gums and celluloses, such as hydroxypropyl guar gum, methylhydroxyethylcellulose or hydroxypropylmethylcellulose, and silicone gums, for instance a polydimethylsiloxane derivative.

The compositions of the invention may be prepared according to the techniques that are well known to those skilled in the art, in particular those intended for preparing emulsions of the oil-in-water or water-in-oil type.

These compositions may be in particular in the form of a dispersion, especially an aqueous dispersion, a simple or complex emulsion (O/W, W/O, O/W/O or W/O/W emulsion) such as a cream, a milk or a cream-gel, a powder or a solid tube, and may optionally be packaged as an aerosol and may be in the form of a mousse or a spray.

When it is an emulsion, the aqueous phase of the said emulsion may comprise a nonionic vesicular dispersion prepared according to known processes (Bangham, Standish and Watkins, J. Mol. Biol. 13, 238 (1965), FR 2315991 and FR 2416008).

The cosmetic compositions according to the invention may be used as compositions for protecting the human epidermis or the hair against ultraviolet rays, as antisen compositions or as makeup products.

When the cosmetic compositions according to the invention are used for protecting the human epidermis against UV rays or for antisen compositions, they may be in the form of a suspension or a dispersion in fatty substances, in the form of a nonionic vesicular dispersion or in the form of an emulsion, preferably of oil-in-water type, such as a cream or a milk, or in the form of an ointment, a gel, a solid tube, a stick, an aerosol mousse or a spray.

When the cosmetic compositions according to the invention are used for protecting the hair, they may be in the form of a shampoo, a lotion, a gel, an emulsion or a nonionic vesicular dispersion. They may constitute, for example, a rinse-out composition, to be applied before or after shampooing, before or after dyeing or bleaching, or before, during or after permanent-waving or relaxing the hair, a styling or treating lotion or gel, a blow-drying or hairsetting lotion or gel, or a composition for permanent-waving, relaxing, dyeing or bleaching the hair.

When the cosmetic compositions according to the invention are used as makeup products for the eyelashes, the eyebrows or the skin, such as an epidermal treatment cream, a foundation, a tube of lipstick, an eyeshadow,

a makeup rouge, a mascara or an eyeliner, they may be in solid or pasty, anhydrous or aqueous form, for instance oil-in-water or water-in-oil emulsions, nonionic vesicular dispersions or suspensions.

The examples that follow are intended to illustrate the invention.

5

Example 1

The block copolymer is dissolved in dichloromethane with excess DHEA. The solvent is evaporated off under reduced pressure using a rotary evaporator. The film formed is then hydrated with distilled water, with
10 stirring, at a temperature of between 20 and 80°C, for 2 hours. The polymer content in the water is of the order of one percent. 24 hours later, this suspension is centrifuged so as to separate out the DHEA not encapsulated in the polymer micelles.

The supernatant is taken up and then assayed by HPLC.

15

Chemical nature	Solubility	Solubility gain	DHEA/polymer mass ratio	MW	A/B or A/B/A
Water	0.001				
PS-POE	0.061	61	1.22%	2000	1000/1000
PS-POE	0.036	36	0.72%	4000	1000/3000
Poly(methyl methacrylate)/POE	0.055	55	1.10%	2000	1000/1000
Poly(methyl methacrylate)/POE	0.023	23	0.46%	4000	1000/3000
Poly(butyl methacrylate)/POE	0.052	25	1.04%	2000	1000/1000
Poly(butyl methacrylate)/POE	0.034	34	0.68%	4000	1000/3000
POE-POB-POE	0.031	31	0.62%	9000	3500/2000/3500
PS-POE	0.01	10	0.20%	10 600	3600/7000
PS-POE	0.06	60	1.20%	9000	3900/5100
PS-POE/PS-POE (90/10)	0.02	20	0.40%		3600/7000/12200/23900

PS-POE/PS-POE (90/10)	0.08	80	1.60%		3900/5100/ 12200/239 00
POE-POP-POE (com- parative)	0.005	5	0.10%	14 600	128/54/128
POE-POP-POE (com- parative)	0.002	2	0.04%	8400	75/30/75
POE-POP-POE (com- parative)	0.003	1	0.06%	2200	
POE-POP-POE (com- parative)	0.002	2	0.04%	4700	46/16/46

PS: polystyrene

POE: polyoxyethylene

POP: polyoxypropylene

POB: polyoxybutylene

5

The solubility gain is calculated relative to the "natural" solubility of the lipophilic compound in water.

It is found that the POE-POP-POE block copolymers do not make it possible to dissolve the DHEA sufficiently (less than fifteen times).

- 10 On the other hand, the polymers according to the invention, for instance PS-POE, methyl methacrylate-POE, butyl methacrylate-POE or POE-POB-POE, make it possible to improve the solubility of DHEA in water, up to 80 times.

15 **Example 2**

The block polymer is dissolved in dichloromethane with excess Parsol® 1789. The solvent is evaporated off under reduced pressure using a rotary evaporator. The film formed is then hydrated with distilled water, with stirring, at a temperature of between 20 and 80°C, for 2 hours. The polymer

20 content in the water is of the order of one percent. 24 hours later, this suspension is centrifuged in order to separate out the Parsol® 1789 that has not been encapsulated in the polymer micelles. The supernatant, which should not contain any crystals that may be identified using an optical microscope in polarized light, is taken up and then assayed by

- 25 HPLC.

Chemical nature	Solubility mg/ml	Solubility gain	Parsol 1789/ polymer mass ratio	A/B or A/B/A
Water	0.001			
PS-POE	0.686	686	3.43%	1000/1000
PS-POE	0.34	340	1.70%	1000/3000
Methyl methacrylate/POE	0.862	862	4.31%	1000/1000
Methyl methacrylate/POE	0.43	430	2.15%	1000/3000
Butyl methacrylate/POE	1.008	1008	5.04%	1000/1000
Butyl methacrylate/POE	0.475	475	2.37%	1000/3000
POE-POB-POE	0.230	230	1.18%	3500/2000/3500
PDMS/OE/OP	0.171	171	0.85%	PDMS/OE/OP
PDMS/OE/OP	0.186	186	0.93%	PDMS/OE/OP
PS-POE	0.171	171	0.85%	3600/7000
PS-POE	0.185	185	0.92%	3900/5100
PS-POE/PS-POE (90/10)	0.53	530	2.65%	3600/7000/12200/23900
PS-POE/PS-POE (90/20)	0.453	453	2.26%	3900/5100/12200/23900
PS-POE	0.529	529	2.64%	2300/3100
P(caprolactone)-POE	0.316	316	1.58%	800/5000
P(caprolactone)-POE	0.635	635	3.17%	1370/5000
PE-POE	0.164	164	0.82%	5000/5900
PE-POE	0.124	124	0.62%	4800/4800
POE-POP-POE (comparative)	0.006	6	0.03%	75/30/75

PS: polystyrene
 POE: polyoxyethylene
 POP: polyoxypropylene
 POB: polyoxybutylene

5

The solubility gain is calculated relative to the "natural" solubility of the lipophilic compound in water.

Surprisingly, in this case also, the block copolymers according to the invention dissolve the lipophilic compound better than do the POE-POP-

10 POE block copolymers.

Example 3 : Oil-in-water emulsion

Oily phase:

Diglyceryl monostearate	2.0	%
PEG-20 stearate	1.5	%
Disodium N-stearoyl-L-glutamic acid (Acyl glutamate HS 21 from Ajinomoto)	0.5	%
Liquid petroleum jelly	3	%
Petroleum jelly	1	%
Stearyl heptanoate	3	%
Apricot kernel oil	5	%
Hydrogenated polyisobutene	5	%
Isocetyl palmitate	2	%
Volatile silicone	5	%
Vitamin E	0.5	%
Preserving agent	0.3	%

Aqueous phase 1

Glycerol		5	%
Preserving agents		1	%
Distilled water	qs	100	%

Aqueous phase 2

Carbomer	0.4	%
Distilled water	15	%
Preserving agents	0.1	%
Triethanolamine	0.4	%

Aqueous phase 3

Aqueous suspension of ME 10-10

(methyl methacrylate/POE 1000/1000)
 at 20% in water, containing 8% Parsol® 1789 10 %

Procedure: The aqueous phase 1 is introduced at 60°C into the oily phase at 60°C, with very vigorous stirring. The temperature and the stirring are maintained for 30 minutes. The suspension is then cooled to room temperature. The aqueous phase 2 is then dispersed using a non-shear disperser. The aqueous phase 3 (micellar suspension) is then introduced with gentle stirring.

Example 4 : Oil-in-water emulsion

10

Oily phase:

Diglyceryl monostearate	2.0	%
PEG-20 stearate	1.5	%
Disodium N-stearoyl-L-glutamic acid (Acyl glutamate HS 21 from Ajinomoto)	0.5	%
Liquid petroleum jelly	3	%
Petroleum jelly	1	%
Stearyl heptanoate	3	%
Apricot kernel oil	5	%
Hydrogenated polyisobutene	5	%
Isocetyl palmitate	2	%
Volatile silicone	5	%
Vitamin E	0.5	%
Preserving agent	0.3	%

Aqueous phase 1

Glycerol	5	%
Preserving agents	1	%
Distilled water	qs	100 %

Aqueous phase 2

Carbomer	0.4	%
Distilled water	15	%
Preserving agents	0.1	%
Triethanolamine	0.4	%

Aqueous phase 3

Aqueous suspension of PS-POE (1000-1000) at 20% in water, containing 1% DHEA relative to the polymer

10 %

- Procedure:** The aqueous phase 1 is introduced at 60°C into the oily phase at 60°C, with very vigorous stirring. The temperature and the stirring are maintained for 30 minutes. The suspension is then cooled to room temperature. The aqueous phase 2 is then dispersed using a non-shear disperser. The aqueous phase 3 (micellar suspension) is then introduced with gentle stirring.

Example 5

10

An essential oil of lavender is dissolved, forming a micellar suspension of butyl methacrylate-POE (1000-1000)

Aqueous phase 1

Butyl methacrylate-POE (1000-1000)	10	%
Essential oil of lavender	0.15	%
Distilled water	80	%

Aqueous phase 2

Glycerol	3	%
Preserving agents	0.3	%
Distilled water	qs	100 %

- Procedure:** The aqueous phase 1 is heated to 60°C and is then mixed with stirring with the aqueous phase 2, which has itself been preheated to 60°C. The temperature and the stirring are maintained for 30 minutes. The composition is then cooled to room temperature.


CLAIMS

1. Process for dissolving at least one lipophilic compound in an aqueous phase, characterized in that it comprises the step of associating the said lipophilic compound with an effective amount of at least one amphiphilic block copolymer comprising at least one ionic and/or at least one nonionic hydrophilic polymer block, and at least one hydrophobic polymer block obtained from at least one hydrophobic monomer chosen from :
- 10 - styrene and its derivatives such as 4-butylstyrene,
 - vinyl acetate of formula $\text{CH}_2=\text{CH}-\text{OCOCH}_3$,
 - vinyl ethers of formula $\text{CH}_2=\text{CHOR}$ in which R is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms,
 - 15 - acrylonitrile,
 - vinyl chloride and vinylidene chloride,
 - caprolactone and caprolactam,
 - alkenes such as ethylene, propylene, butylene and butadiene,
 - alkylene oxides containing at least 4 carbon atoms and preferably from 4
 - 20 to 6 carbon atoms,
 - silicone derivatives producing, after polymerization, silicone polymers such as polydimethylsiloxane,
 - hydrophobic vinyl monomers of formula (A) below:
- $$\begin{array}{c} \text{H}_2\text{C}=\text{CR} \\ | \\ \text{CO} \\ | \\ \text{X} \end{array} \quad (\text{A})$$
- 25 in which:
 - R is chosen from H, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$ and $-\text{C}_3\text{H}_7$,
 - X is chosen from:
 - alkyl oxides of $-\text{OR}'$ type in which R' is a linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to
 - 30 22 carbon atoms, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a sulphonate group ($-\text{SO}_3^-$), a sulphate group ($-\text{SO}_4^-$), a phosphate group ($-\text{PO}_4\text{H}_2^-$); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$), a tertiary amine group ($-\text{NR}_1\text{R}_2$) or a quaternary amine group ($-\text{N}^+\text{R}_1\text{R}_2\text{R}_3$) with R_1 , R_2 and
 - 35 R_3 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of $\text{R}' + \text{R}_1 + \text{R}_2 + \text{R}_3$ does not exceed 22; R' may also be a perfluoroalkyl radical, preferably containing from 1 to 18 carbon atoms;

--NH₂, -NHR' and -NR'R'' groups in which R' and R'' are, independently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 22 carbon atoms, with the proviso that the total number of carbon atoms of R' + R'' does not exceed 22, R' and R'' optionally being substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group (-OH); a sulphonic group (-SO₃⁻); a sulphate group (-SO₄⁻); a phosphate group (-PO₄H₂⁻); a primary amine group (-NH₂); a secondary amine group (-NHR₁), a tertiary amine group (-NR₁R₂) and/or a quaternary amine group (-N⁺R₁R₂R₃) with R₁, R₂ and R₃ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R'' + R₁ + R₂ + R₃ does not exceed 22; R' and R'' may also be perfluoroalkyl radicals, preferably containing from 1 to 18 carbon atoms.

2. Process according to claim 1, characterized in that the ionic hydrophilic polymer block is polyethyleneimine or is obtained from water-soluble monomers or salts thereof, chosen from

- (meth)acrylic acid,
- acrylamido-2-methylpropanesulphonic (AMPS) acid,
- styrenesulphonic acid,
- vinylsulphonic acid and (meth)allylsulphonic acid,
- vinylphosphonic acid,
- maleic anhydride,
- itaconic acid,
- dimethyldiallylammonium chloride,
- quaternized dimethylaminoethyl methacrylate (DMAEMA),
- (meth)acrylamidopropyltrimethylammonium chloride (APTAC and MAPTAC),
- methylvinylimidazolium chloride,
- hydrophilic vinyl monomers of formula (A) below:




in which:

- R is chosen from H, -CH₃, -C₂H₅ and -C₃H₇,
- X is chosen from:

- alkyl oxides of -OR' type in which R' is a linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, substituted with at least one sulphonic group (-SO₃⁻)

- and/or sulphate group ($-\text{SO}_4^-$) and/or phosphate group ($-\text{PO}_4\text{H}_2^-$) and/or quaternary amine group ($-\text{N}^+\text{R}_1\text{R}_2\text{R}_3$) with R_1 , R_2 and R_3 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the atoms of $\text{R}' + \text{R}_1 + \text{R}_2 + \text{R}_3$ does not exceed 6; the radical R' being optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R_1 , R_2 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of $\text{R}' + \text{R}_1 + \text{R}_2$ does not exceed 6;
- $-\text{NH}_2$, $-\text{NHR}'$ and $-\text{NR}'\text{R}''$ groups in which R' and R'' are, independently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 6 carbon atoms, with the proviso that the total number of carbon atoms of $\text{R}' + \text{R}''$ does not exceed 6, R' and/or R'' optionally being substituted with at least one sulphonc group ($-\text{SO}_3^-$) and/or sulphate group ($-\text{SO}_4^-$) and/or phosphate group ($-\text{PO}_4\text{H}_2^-$) and/or quaternary amine group ($-\text{N}^+\text{R}_1\text{R}_2\text{R}_3$) with R_1 , R_2 and R_3 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the atoms of $\text{R}' + \text{R}_1 + \text{R}_2 + \text{R}_3$ does not exceed 6; the radicals R' and/or R'' being optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R_1 , R_2 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of $\text{R}' + \text{R}'' + \text{R}_1 + \text{R}_2$ does not exceed 6.
3. Process according to any one of the preceding claims, characterized in that the ionic hydrophilic block is chosen from (meth)acrylic acid.
4. Process according to any one of the preceding claims, characterized in that the nonionic hydrophilic polymer block is of polyoxyalkylenated type, for instance polyoxyethylene, or is polyvinylpyrrolidone (PVP), or is obtained from water-soluble monomers chosen from
- (meth)acrylamide,
 - N-vinylacetamide and N-methyl-N-vinylacetamide,
 - N-vinylformamide and N-methyl-N-vinylformamide,

- N-vinyl lactams comprising a cyclic alkyl group containing from 4 to 9 carbon atoms, such as N-vinylpyrrolidone, N-butyrolactam and N-vinylcaprolactam,
- vinyl alcohol of formula $\text{CH}_2=\text{CHOH}$,
- 5 - glycidyl (meth)acrylate,
- hydrophilic vinyl monomers of formula (A) below:



in which:

- 10 - R is chosen from H, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$ and $-\text{C}_3\text{H}_7$,
- X is chosen from:
 - alkyl oxides of $-\text{OR}'$ type in which R' is a linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$);
 - 15 a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R_1 and R_2 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of R' +
 - 20 $\text{R}_1 + \text{R}_2$ does not exceed 6;
 - $-\text{NH}_2$, $-\text{NHR}'$ and $-\text{NR}'\text{R}''$ groups in which R' and R'' are, independently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 6 carbon atoms, with the proviso that the total number of carbon atoms of R' + R'' does not exceed 6,
 - 25 R' and R'' optionally being substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$) or a tertiary amine group ($-\text{NR}_1\text{R}_2$) with R_1 and R_2 being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing
 - 30 from 1 to 6 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R'' + $\text{R}_1 + \text{R}_2$ does not exceed 6.


5. Process according to Claim 4, characterized in that the nonionic hydrophilic polymer block is chosen from polyethylene oxide and polyvinylpyrrolidone.

35

6. Process according to any one of the preceding claims, characterized in that the hydrophilic polymer block is nonionic.

7. Process according to any one of the preceding claims, characterized in that the hydrophobic polymer block is obtained from at least one hydrophobic monomer chosen from styrene, tert-butylstyrene, methyl methacrylate, ethyl (meth)acrylate, n-butyl (meth)acrylate, tert-butyl (meth)acrylate, cyclohexyl acrylate, isobornyl acrylate, 2-ethylhexyl acrylate, ethyl perfluorooctyl acrylate, trifluoromethyl (meth)acrylate, polybutylene oxide or polyoxybutylene (POB), butadiene, ethylene, propylene and butylene.
8. Process according to any one of the preceding claims, characterized in that the block copolymer is chosen from the following block copolymers:
- polystyrene/polyoxyethylene
 - polymethyl methacrylate/polyoxyethylene
 - polybutyl methacrylate/polyoxyethylene
 - polyoxybutylene/polyoxyethylene
 - polycaprolactone/polyoxyethylene
 - polyethylene/polyoxyethylene
 - polyoxyethylene/polyoxybutylene/polyoxyethylene.
9. Process according to any one of the preceding claims, characterized in that the molecular weight of the block copolymer is between 1 000 and 500 000, preferably from 2000 to 100 000.
10. Process according to any one of the preceding claims, characterized in that the weight ratio A/B between the hydrophilic block A and the hydrophobic block B ratio is between 1/100 and 50/1.
11. Process according to any one of the preceding claims, characterized in that the weight concentration ratio between the lipophilic compound and the amphiphilic block copolymer is between 0.005 and 0.5 and preferably between 0.005 and 0.2.
12. Process according to any one of the preceding claims, characterized in that the lipophilic compound is chosen from :
- emollients, anti-inflammatory agents, antibacterial agents, antifungal agents, antiviral agents, anti-seborrhoeic agents, antiacne agents, keratolytic agents, antihistamines, anaesthetics, cicatrizing agents, pigmentation modifiers, tanning accelerators, artificial tanning agents, liporegulators, anti-ageing and anti-wrinkle agents, refreshing agents, vascular protectors, insect repellants, deodorants, antidandruff agents, agents for preventing hair loss,

- essential oils, which may be chosen especially from eucalyptus oil, lavandin oil, lavender oil, vetiver oil, Litsea cubeba oil, lemon oil, sandalwood oil, rosemary oil, camomile oil, savory oil, nutmeg oil, cinnamon oil, hyssop oil, caraway oil, orange oil, geraniol oil and cade oil, fragrances,
- 5 - sunscreens, antioxidants, free-radical scavengers and moisturizers;
- vitamins such as vitamin A (retinol) or esters thereof, vitamin E or esters thereof such as tocopheryl acetate, vitamin D or derivatives thereof and vitamin F or derivatives thereof; carotenes such as β -carotene and derivatives thereof such as lycopene, and salicylic acid derivatives;
- 10 - dehydroepiandrosterone (DHEA) and its biological precursors and derivatives, with the exception of cholesterol and its esters and plant sterols such as phytosterols and sitosterols, and esters thereof,
- pentacyclic triterpene acids such as ursolic acid and oleanolic acid,
- hydroxystilbenes,
- 15 - isoflavonoids,
- aminophenol derivatives of formula



in which R is a radical corresponding to one of the formulae (i), (ii) or (iii) below

- 20 (i) $-\text{CO}-\text{NR}_1\text{R}_2$
- (ii) $-\text{CO}-\text{O}-\text{R}_3$
- (iii) $-\text{SO}_2-\text{R}_3$

in which

- R_1 represents a hydrogen atom or a linear or branched, saturated or
- 25 unsaturated, optionally hydroxylated C_{1-6} alkyl radical,
- R_2 represents a hydrogen atom or a radical chosen from saturated or unsaturated, linear, cyclic or branched, C_{12} to C_{30} optionally hydroxylated alkyl radicals, and
- R_3 represents a radical chosen from saturated or unsaturated, linear,
- 30 branched or cyclic C_{12} to C_{30} alkyl radicals, including fused polycyclic radicals, which are optionally hydroxylated.

13. Process according to Claim 12, characterized in that the salicylic acid derivatives are chosen from the 5-n-octanoylsalicylic, 5-n-decanoylsalicylic,
- 35 5-n-dodecanoylsalicylic, 5-n-octylsalicylic, 5-n-heptyloxysalicylic, 4-n-heptyloxysalicylic, 5-tert-octylsalicylic, 3-tert-butyl-5-methylsalicylic, 3-tert-butyl-6-methylsalicylic, 3,5-diisopropylsalicylic, 5-butoxysalicylic, 5-octyloxysalicylic, 5-propanoylsalicylic, 5-n-hexadecanoylsalicylic,

5-n-oleoylsalicylic and 5-benzoylsalicylic acid derivatives, monovalent and divalent salts thereof, and mixtures thereof.

14. Process according to Claim 12, characterized in that the sunscreens
5 are chosen from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives; camphor derivatives; triazine derivatives, preferably 1,3,5-triazine derivatives; benzophenone derivatives; β,β' -diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bis-benzazoly
10 derivatives; p-aminobenzoic acid (PABA) derivatives; methylene-bis(hydroxyphenylbenzotriazole) derivatives; screening polymers and screening silicones; dimers derived from α -alkylstyrene; 4,4-diarylbutadienes, and mixtures thereof.
15. Process according to Claim 14 characterized in that the 1,3,5-triazine derivatives are chosen from the following compounds:
- 2-[(p-(tert-butylamido)anilino]-4,6-bis[(p-(2'-ethylhexyl-1'-oxycarbonyl)anilino]-1,3,5-triazine,
- 2,4,6-tris[p'-(2'-ethylhexyl-1'-oxycarbonyl)anilino]-1,3,5-triazine,
20 - 2,4-bis[[4-2-ethylhexyloxy]-2-hydroxy]phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine,
- 2,4,6-tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine, and mixtures thereof.
- 25 16. Process according to Claim 14, characterized in that the dibenzoylmethane derivative is butylmethoxydibenzoylmethane.
17. Process according to Claim 12, characterized in that the lipophilic compound is chosen from dehydroepiandrosterone (DHEA), DHEA sul-
30 phate, 7-hydroxy-DHEA, 7-keto-DHEA, prednisolone, prednisone, progesterone, pregnenolone, testosterone, diosgenin, hecogenin, ursolic acid, oleanolic acid, resveratrol and N-cholesteryloxycarbonyl-4-aminophenol, and isoflavonoids whose solubility in water at room temperature (25°C) is less than 0.01%.
- 35 18. Cosmetic composition comprising at least one aqueous phase, at least one lipophilic compound and an effective amount of at least one block amphiphilic copolymer comprising at least one ionic and/or at least one nonionic hydrophilic polymer block, and at least one hydrophobic polymer
40 block obtained from at least one hydrophobic monomer chosen from :
- styrene and its derivatives such as 4-butylstyrene,

- vinyl acetate of formula $\text{CH}_2=\text{CH}-\text{OCOCH}_3$,
 - vinyl ethers of formula $\text{CH}_2=\text{CHOR}$ in which R is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms,
 - 5 - acrylonitrile,
 - vinyl chloride and vinylidene chloride,
 - caprolactone and caprolactam,
 - alkenes such as ethylene, propylene, butylene and butadiene,
 - alkylene oxides containing at least 4 carbon atoms and preferably from 4
 - 10 to 6 carbon atoms,
 - silicone derivatives producing, after polymerization, silicone polymers such as polydimethylsiloxane,
 - hydrophobic vinyl monomers of formula (A) below:
- $$\begin{array}{c}
 \text{H}_2\text{C}=\text{CR} \\
 | \\
 \text{CO} \\
 | \\
 \text{X}
 \end{array}
 \quad (\text{A})$$
- 15 in which:
 - R is chosen from H, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$ and $-\text{C}_3\text{H}_7$,
 - X is chosen from:
 - alkyl oxides of $-\text{OR}'$ type in which R' is a linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to
 - 20 22 carbon atoms, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine); a sulphonic group ($-\text{SO}_3^-$), a sulphate group ($-\text{SO}_4^-$), a phosphate group ($-\text{PO}_4\text{H}_2^-$); a hydroxyl group ($-\text{OH}$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$), a tertiary amine group ($-\text{NR}_1\text{R}_2$) or a quaternary amine group ($-\text{N}^+\text{R}_1\text{R}_2\text{R}_3$) with R₁, R₂ and
 - 25 R₃ being, independently of each other, a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R₁ + R₂ + R₃ does not exceed 22; R' may also be a perfluoroalkyl radical, preferably containing from 1 to 18 carbon atoms;
 - 30 - $-\text{NH}_2$, $-\text{NHR}'$ and $-\text{NR}'\text{R}''$ groups in which R' and R'' are, independently of each other, linear, cyclic or branched, saturated or unsaturated hydrocarbon-based radicals containing from 1 to 22 carbon atoms, with the proviso that the total number of carbon atoms of R' + R'' does not exceed 22, R' and R'' optionally being substituted with a halogen atom (iodine,
 - 35 bromine, chlorine or fluorine); a hydroxyl group ($-\text{OH}$); a sulphonic group ($-\text{SO}_3^-$); a sulphate group ($-\text{SO}_4^-$); a phosphate group ($-\text{PO}_4\text{H}_2^-$); a primary amine group ($-\text{NH}_2$); a secondary amine group ($-\text{NHR}_1$), a tertiary amine group ($-\text{NR}_1\text{R}_2$) and/or a quaternary amine group ($-\text{N}^+\text{R}_1\text{R}_2\text{R}_3$) with R₁, R₂ and R₃ being, independently of each other, a linear or branched, saturated

or unsaturated hydrocarbon-based radical containing from 1 to 22 carbon atoms, with the proviso that the sum of the carbon atoms of R' + R'' + R_1 + R_2 + R_3 does not exceed 22; R' and R'' may also be perfluoroalkyl radicals, preferably containing from 1 to 18 carbon atoms.

5

19. Composition according to claim 18, characterized in that the weight concentration ratio between the lipophilic compound and the amphiphilic block copolymer is between 0.005 and 0.5 and preferably between 0.005 and 0.2.

10

20. Composition according to any one of Claims 18 to 19, characterized in that the lipophilic compound is present in the composition in weight contents of between 0.001% and 10% of the total weight of the composition.

15

21. Composition according to any one of Claims 18 to 20, characterized in that it also contains one or more formulation adjuvants chosen from pigments, nanopigments, fatty substances, organic solvents, thickeners, softeners, free-radical scavengers, stabilizers, emollients, silicones, α -hydroxy acids, antifoams, moisturizers, vitamins, preserving agents, surfactants, fillers, sequestering agents, polymers, propellants, acidifying or basifying agents, dyes, opacifiers.

20

22. Composition according to any one of Claims 18 to 21, characterized in that it is a composition for protecting the human epidermis or the hair against ultraviolet rays, as antisen compositions; or is a makeup product; or is a composition for protecting the hair.

25

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035013 A3

(51) International Patent Classification⁷: A61K 7/42,
7/48, 7/06, B01F 17/00, 17/52, 17/54

(21) International Application Number:
PCT/EP2003/013050

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0213101 21 October 2002 (21.10.2002) FR
60/432,619 12 December 2002 (12.12.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
L'OREAL [FR/FR], 14, rue Royale, F-75008 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): SIMONNET, Jean-Thierry [FR/FR], 53 bis, Avenue Carnot, F-94240 Cachan (FR).

(74) Agent: DODIN, Catherine; L'Oreal - D.I.P.I., 25-29 Quai Aulagnier, F-92600 Asnières (FR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
17 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/035013 A3

(54) Title: PROCESS FOR DISSOLVING LIPOPHILIC COMPOUNDS, AND COSMETIC COMPOSITION

(57) Abstract: The invention relates to a process for dissolving at least one lipophilic compound in at least one aqueous phase, characterized in that it comprises the step of associating the said lipophilic compound with an effective amount of at least one amphiphilic block copolymer comprising at least one ionic and/or at least one nonionic hydrophilic polymer block, and at least one hydrophobic polymer block.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13050

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/42 A61K7/48 A61K7/06 B01F17/00 B01F17/52
B01F17/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K B01F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 127 570 A (NANOCARRIER CO LTD) 29 August 2001 (2001-08-29) claims 1-3,7	1-6,8-11
X	WO 01/12718 A (SEO MIN HYO ;CHOI IN JA (KR); SAMYANG CORP (KR)) 22 February 2001 (2001-02-22) claim 15; example 9; table 1	1,4-6, 8-12
X	US 6 322 805 B1 (KIM SUNG-CHUL ET AL) 27 November 2001 (2001-11-27) claim 1; examples 1,2; table 1	1,4-6, 8-11
X	EP 0 870 781 A (BASF AG) 14 October 1998 (1998-10-14) page 5, lines 9-14; claims 1-10 -/-	1,9,10, 12,18, 21,22

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

26 April 2004

Date of mailing of the international search report

04/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

de La Morinerie, B

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/13050

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 085 902 A (OREAL) 31 December 1971 (1971-12-31) the whole document	18,21,22
X	FR 2 155 901 A (OREAL) 25 May 1973 (1973-05-25) the whole document	18,21
X	FR 2 140 977 A (OREAL) 19 January 1973 (1973-01-19) the whole document	18,21,22
X	EP 1 125 574 A (GOLDSCHMIDT AG TH) 22 August 2001 (2001-08-22) the whole document	18,21,22
X	WO 00/12660 A (JAKOBS BRITTA ;RICHTER DIETER (DE); SOTTMANN THOMAS (DE); STREY RE) 9 March 2000 (2000-03-09) page 4 - page 5	1-10
P,X	EP 1 302 197 A (OREAL) 16 April 2003 (2003-04-16) claims 1-4	1-10, 12-15, 18,21,22
P,X	EP 1 281 395 A (OREAL) 5 February 2003 (2003-02-05) the whole document	1-10, 12-18, 20-22
A	WO 99/47589 A (CREPEAU COLETTE ;HOERNER PIERRE (FR); HUTCHINSON (FR); RIESS GERAR) 23 September 1999 (1999-09-23) the whole document	1-22

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 03/13050

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1127570	A	29-08-2001	JP 2001226294 A	21-08-2001
			CA 2334615 A1	09-08-2001
			CN 1307866 A	15-08-2001
			EP 1127570 A2	29-08-2001
			US 2004056372 A1	25-03-2004
			US 2001014354 A1	16-08-2001
WO 0112718	A	22-02-2001	KR 2001017804 A	05-03-2001
			AU 763154 B2	17-07-2003
			AU 6479200 A	13-03-2001
			CA 2381729 A1	22-02-2001
			CN 1370201 T	18-09-2002
			EP 1226212 A1	31-07-2002
			JP 3363142 B1	08-01-2003
			JP 2003507514 T	25-02-2003
			WO 0112718 A1	22-02-2001
			NZ 517036 A	25-07-2003
			US 6616941 B1	09-09-2003
US 6322805	B1	27-11-2001	KR 180334 B1	20-03-1999
			AU 699988 B2	17-12-1998
			AU 7098096 A	09-04-1997
			CA 2231886 A1	27-03-1997
			CN 1197396 A	28-10-1998
			DE 69625921 D1	27-02-2003
			DE 69625921 T2	07-08-2003
			EP 0854731 A1	29-07-1998
			ES 2188787 T3	01-07-2003
			JP 10512287 T	24-11-1998
			WO 9710849 A1	27-03-1997
EP 0870781	A	14-10-1998	DE 19714714 A1	15-10-1998
			CN 1199744 A	25-11-1998
			EP 0870781 A1	14-10-1998
			JP 10292022 A	04-11-1998
FR 2085902	A	31-12-1971	AT 307622 B	25-05-1973
			AT 325211 B	10-10-1975
			BE 765266 A1	05-10-1971
			BE 789729 A4	05-04-1973
			CA 964196 A1	11-03-1975
			CH 532954 A	31-01-1973
			DE 2116787 A1	21-10-1971
			ES 389931 A1	16-03-1974
			FR 2085902 A5	31-12-1971
			GB 1324745 A	25-07-1973
			IT 988318 B	10-04-1975
			LU 60676 A1	10-02-1972
			NL 7104613 A ,B,	11-10-1971
			SE 359737 B	10-09-1973
			US 4032628 A	28-06-1977
FR 2155901	A	25-05-1973	FR 2155901 A2	25-05-1973
			AR 192668 A1	28-02-1973
			AT 325211 B	10-10-1975
			BE 789729 A4	05-04-1973
			CA 977682 A1	11-11-1975
			CH 552406 A	15-08-1974

Form PCT/ISA/210 (patent family annex) (January 2004)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/13050

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2155901 A		DE 2248745 A1	12-04-1973
		GB 1383005 A	05-02-1975
		IT 1024514 B	20-07-1978
		NL 7213519 A	10-04-1973
		US 4032628 A	28-06-1977
FR 2140977 A	19-01-1973	FR 2140977 A5	19-01-1973
EP 1125574 A	22-08-2001	CA 2335663 A1	19-08-2001
		EP 1125574 A2	22-08-2001
		JP 2001247452 A	11-09-2001
		PL 345923 A1	27-08-2001
		US 2001046507 A1	29-11-2001
WO 0012660 A	09-03-2000	DE 19839054 A1	02-03-2000
		WO 0012660 A2	09-03-2000
		EP 1109883 A2	27-06-2001
		JP 2002525392 T	13-08-2002
		US 2004054064 A1	18-03-2004
		US 6677293 B1	13-01-2004
EP 1302197 A	16-04-2003	FR 2830773 A1	18-04-2003
		BR 0204115 A	16-09-2003
		CA 2405040 A1	11-04-2003
		CN 1428141 A	09-07-2003
		EP 1302197 A1	16-04-2003
		JP 2003137719 A	14-05-2003
		US 2003129151 A1	10-07-2003
EP 1281395 A	05-02-2003	FR 2827513 A1	24-01-2003
		CN 1415280 A	07-05-2003
		EP 1281395 A1	05-02-2003
		JP 2003055137 A	26-02-2003
		US 2003059391 A1	27-03-2003
WO 9947589 A	23-09-1999	EP 0981573 A1	01-03-2000
		WO 9947589 A1	23-09-1999
		JP 2002501572 T	15-01-2002
		US 6391326 B1	21-05-2002

Form PCT/ISA/210 (patent family annex) (January 2004)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)